Results 191 to 200 of about 152,832 (396)

Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real‐life multicenter study

Headache: The Journal of Head and Face Pain, EarlyView.
Plain Language Summary This study shows that galcanezumab is equally effective and well‐tolerated in patients aged 65 and older as in younger patients, with a higher proportion of excellent responders in older patients. Despite having more baseline headache days, older patients responded well to the treatment, with age being linked to better outcomes ...
Julia Peris‐Subiza, Víctor Obach, Daniel Guisado‐Alonso, Fernando Velasco Juanes, Rocío Álvarez Escudero, María Martín Bujanda, Sonsoles Aranceta, Aintzine Ruisánchez, Natalia Roncero, Ane Mínguez‐Olaondo, Amaya Echeverria, Alba López‐Bravo, Ángel Luis Guerrero‐Peral, David García‐Azorín, Elisa Cuadrado‐Godia, Galca‐Only Study Group, Neus Fabregat, Marta Ruibal, Izaro Kortazar Zubizarreta, Nuria Riesco, Lucia González‐Fernández, Paula Manera, Agustín Oterino Duran, Yésica González‐Osorio, Santiago Fernández‐Fernández, Juan Carlos García‐Moncó, Isabel Fernández‐Pérez, Joan Jiménez‐Balado   +27 more
wiley   +1 more source

Calcitonin gene-related peptide: physiology and pathophysiology.

Physiological Reviews, 2014
F. Russell, R. King, Sarah-Jane Smillie, X. Kodji, S. Brain   +4 more
semanticscholar   +1 more source

Radioimmunoassay of calcitonin in the plasma of rhesus monkey and man.

, 1978
GARY K. HARGIS, W. Ann Reynolds, GERALD A. WILLIAMS, WANDA KAWAHARA, B. Jackson, E. N. Bowser, R M Pitkin   +6 more
openalex   +1 more source

Can atogepant be a preventive treatment for cluster headache?—Insights from a case series

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Cluster headache (CH) is a disabling primary headache disorder with limited therapeutic options. Calcitonin gene‐related peptide (CGRP) is known to be involved in CH pathophysiology; however, except for galcanezumab (300 mg) in episodic CH, anti‐CGRP monoclonal antibodies did not reduce CH attacks in randomized clinical trials. Atogepant is an
Catarina Serrão, Filipa Dourado Sotero, Linda Azevedo Kauppila, Isabel Pavão Martins   +3 more
wiley   +1 more source

Comprehensive assessment of erenumab efficacy in participants with high‐frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To evaluate the effect of erenumab treatment beyond monthly migraine days in patients with high‐frequency episodic migraine who did not respond to at least one previous migraine preventive treatment. Background Reduction in monthly migraine days has been the efficacy standard for migraine preventive treatments; however, it does not ...
Gabriel Paiva da Silva Lima, Renata Rao, Gyöngyi Szabó, Sebastian Szklener, Cristina Tassorelli, Marcin Nastaj, Denise E. Chou, Ani C. Khodavirdi, Mahan Chehrenama, Yineng Zhu, Ajay K. Bhatia, David W. Dodick   +11 more
wiley   +1 more source

A phase 1, multicenter, open‐label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To evaluate pharmacokinetics (PK), safety, and tolerability of a weight‐adjusted dose of rimegepant orally disintegrating tablet (ODT) in children (aged ≥6 to <12 years) with a history of migraine. Background Rimegepant 75 mg ODT is approved for acute treatment of migraine (with or without aura) and preventive treatment of episodic ...
Chay Ngee Lim, Gary Mo, Rajinder Bhardwaj, Craig M. Comisar, Beth L. Emerson, Kyle T. Matschke, Ogert Fisniku, Richard Bertz, Robert Croop, Jing Liu   +9 more
wiley   +1 more source

Persistent postural‐perceptual dizziness versus vestibular migraine: A narrative review

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This article reviews the differences and similarities between persistent postural‐perceptual dizziness (PPPD) and vestibular migraine. Background PPPD is considered a chronic functional vestibular disorder characterized by persistent dizziness, unsteadiness, nonspinning vertigo, and often exacerbated by upright posture, movement, or ...
David Moreno‐Ajona
wiley   +1 more source

Effect of calcitonin treatment on deafness due to Paget's disease of bone. [PDF]

, 1977
L. R. Solomon, John M. Evanson, D P Canty, N W Gill   +3 more
openalex   +1 more source

TRPM3 activation causes CGRP release in trigeminal neurons: Implications for migraine mechanisms

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Background The transient receptor potential melastatin 3 (TRPM3) ion channel has been implicated in sensory modulation and pain transmission and may contribute to migraine pathophysiology through calcitonin gene‐related peptide (CGRP) release in the trigeminovascular system. This study aimed to investigate TRPM3 activation and its role in CGRP
Philip V. Reducha, Lukas K. S. Nielsen, Mette N. Jensen, Jacob C. A. Edvinsson, Spyridoula Kazantzi, Sofia L. Wæver, Tanja Lylloff, Connar S. J. Westgate, Lars Edvinsson, Kristian A. Haanes   +9 more
wiley   +1 more source

The safety and efficacy of long-term use of calcitonin analogs in the treatment of osteoporosis in the elderly: a pharmacovigilance and RCT meta-analysis. [PDF]

Front Pharmacol
Tan L, Sheng B, Deng S.
europepmc   +1 more source